• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

NanoViricides' President Chosen As Special Lecturer at Nanotechnology Conference - Biomedical Applications Attended By Leading Government and Industry Scientists

Posted on: Monday, 11 December 2006, 09:01 CST

NanoViricides, Inc., (Pink Sheets: NNVC)

Dr. Anil Diwan, Company President and Chairman, was selected to speak at "Advances in Nanotechnology Conference - Biomedical Applications, 2006" held at the Moffitt Cancer Center in Tampa, FL, on Dec. 8th. He outlined the significant advantages of the nanoviricides(tm) approach, and the underlying nanomicelle(tm) polymeric micelle technologies, over currently existing technologies.

Dr. Diwan also made it clear that only the nanoviricides technology offers a solution to potential pandemic-causing attacks by novel pathogens, whether they occur as a result of bioterrorism or natural events. This is of major interest to Biodefense professionals. In addition he explained how the Company's technologies can be of significant assistance to the bio-emergency preparedness efforts that are occurring world-wide.

"The leadership position of NanoViricides in the field of NanoMedicine is well recognized," said Eugene Seymour, MD, CEO, about this presentation.

Previously, Dr. Seymour presented the Company's work at the 3rd International Bird Flu Conference in Geneva, Switzerland on November 15th. He stressed the fact to the International Health audience assembled at the Conference that the Company's scientists were working as fast as possible on both avian and seasonal influenza drug developments, "now that it is clear that the nanoviricides are the most efficacious drugs against all influenzas."

NanoViricides also announced that it is on target with its planned studies of H1N1 (common influenza), H5N1 (bird flu), and rabies scheduled for the first quarter 2007, as explained in the Company's filed SEC Form 10SB. The success of these animal studies, to be independently monitored by Vietnamese government scientists, would be expected to result in the creation of drugs with "blockbuster" potential. However even more important to our shareholders and the general public, this will further validate the nanoviricides(tm) technology and hasten the development of drugs by NanoViricides with even larger market sizes such as Hepatitis C (HCV) and HIV.

About NanoViricides - http://www.nanoviricides.com

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.

Source: Business Wire

More News in this Category